Bioregulator
    Research Only

    Cortagen

    Also known as: Cortagen bioregulator, adrenal cortex peptide

    Cortagen is a short synthetic bioregulator peptide developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. It is designed to target the adrenal cortex, supporting the regulation of cortisol production and adrenal gland function. Bioregulator peptides are based on the concept that short peptide sequences derived from or mimicking endogenous tissue-specific peptides can restore gene expression patterns in aging or damaged tissues. Cortagen is proposed to normalise adrenal cortex function by interacting with DNA and modulating transcription of genes involved in androgen-pathway compoundsogenesis. While the bioregulator concept has theoretical appeal, the evidence base consists primarily of preclinical studies and observational reports from Russian clinical practice.

    View Product

    Research overview

    Cortagen represents a bioregulator peptide theorised to function within the bioregulation paradigm developed by Khavinson. This classification encompasses short peptides, typically containing 2-4 amino acids, that are proposed to interact with specific DNA sequences to modulate gene expression in target tissues. In research models, Cortagen is theorised to target the adrenal cortex, where it may normalise transcription of genes involved in cortisol synthesis, aldosterone production, and adrenal stress response mechanisms. The proposed mechanism suggests the peptide could influence chromatin structure and accessibility, potentially restoring gene expression patterns associated with younger adrenal tissue function. Studies indicate potential effects on adrenal cortex function support, with theoretical modulation of cortisol production and broader adrenal gene expression patterns. Research has explored its potential role in androgen-pathway compoundsogenesis bioregulation and stress resilience mechanisms in laboratory settings. The evidence grade for Cortagen is classified as D, indicating extremely limited research foundation. Available evidence consists primarily of preclinical studies and reports from Russian clinical practice that have not undergone independent replication in Western peer-reviewed journals. Whilst the bioregulator peptide concept has theoretical support, specific research data for Cortagen remains sparse, with no randomised controlled trials meeting international standards currently published. Researchers investigating adrenal cortex bioregulation mechanisms may find Cortagen of interest for laboratory studies examining gene expression modulation and androgen-pathway compoundsogenesis pathways, though comprehensive validation studies remain necessary to establish definitive mechanisms and effects.

    Mechanism of action

    Cortagen is theorised to function through the bioregulation paradigm developed by Khavinson, in which short peptides (typically 2-4 amino acids) interact with specific DNA sequences to modulate gene expression in target tissues. For Cortagen, the proposed target is the adrenal cortex, where it is believed to normalise transcription of genes involved in cortisol synthesis, aldosterone production, and adrenal stress response. The peptide may influence chromatin structure and accessibility, potentially restoring youthful gene expression patterns in aging adrenal tissue.

    Frequently asked questions